Design, Synthesis, and Biological Evaluation of a New Imidazole–Pyrazole–Triazole Hybrid: Antidiabetic, and Molecular Docking Studies
ChemistrySelect · 2026-03 · 11 (10)
DOI: 10.1002/slct.202505698 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 09.03.2026. Verfasst von Nagesh Patnam und 6 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Science and Engineering Research Board.
Abstract (Originalsprache)
A novel series of imidazole–pyrazole ‐ 1,2,3‐triazole hybrids ( 7a–b and 8c–j ) were synthesized and evaluated for their in vitro antidiabetic potential through inhibition of the aldose reductase (AR) enzyme. Sorbinil was used as the standard reference inhibitor (IC 50 = 2.01 ± 0.31 µM). Several hybrids exhibited superior inhibitory activity, particularly the fluoro‐substituted analogue 7a , the methoxy derivative 7b , and the methyl analogue 8c , with IC 50 values of 1.20 ± 0.39, 1.88 ± 0.19, and 1.93 ± 0.23 µM, respectively. The trimethoxy analogue 8h also demonstrated potent activity (IC 50 = 2.19 ± 0.36 µM), comparable to Sorbinil . Molecular docking studies were performed using the AR crystal structure (PDB ID: 1PWM), and the docking protocol was validated by re‐docking the co‐crystallized ligand Fidarestat (RMSD = 1.18 Å). All synthesized hybrids showed stronger binding affinities (–13.8—16.3 kcal/mol) compared to Sorbinil (–11.2 kcal/mol). Notably, compound 8c displayed the highest docking score (–16.3 kcal/mol) and formed key stabilizing interactions, including π–π stacking with Trp219 and π‐cation interactions with Leu301 and Ser302. The favorable binding energies and interaction profiles strongly correlate with the observed in vitro activities, highlighting these hybrids as promising AR inhibitors for antidiabetic drug development.
Förderung
- Science and Engineering Research Board
Zitieren
APA
Patnam, N., Chevula, K., Srikanth, M., Jagadish, T., Nagaraju, N., Sagurthi, S. R., & Manga, V. (2026). Design, Synthesis, and Biological Evaluation of a New Imidazole–Pyrazole–Triazole Hybrid: Antidiabetic, and Molecular Docking Studies. ChemistrySelect, 11(10). https://doi.org/10.1002/slct.202505698
Vancouver
Patnam N, Chevula K, Srikanth M, Jagadish T, Nagaraju N, Sagurthi SR, et al. Design, Synthesis, and Biological Evaluation of a New Imidazole–Pyrazole–Triazole Hybrid: Antidiabetic, and Molecular Docking Studies. ChemistrySelect. 2026;11(10). doi:10.1002/slct.202505698
BibTeX
@article{Patnam2026,
author = {Patnam, Nagesh and Chevula, Kishan and Srikanth, Mangalapally and Jagadish, Tota and Nagaraju, Nalaparaju and Sagurthi, Someshwar Rao and Manga, Vijjulatha},
title = {Design, Synthesis, and Biological Evaluation of a New Imidazole–Pyrazole–Triazole Hybrid: Antidiabetic, and Molecular Docking Studies},
journal = {ChemistrySelect},
year = {2026},
volume = {11},
number = {10},
doi = {10.1002/slct.202505698}
}
EUVIMED